Colony-stimulating Factors: Clinical Evidence for Treatment and Prophylaxis of Chemotherapy-induced Febrile Neutropenia

Overview

Journal Clin Transl Oncol

Specialty Oncology

Date 2006 Nov 1

PMID 17074671

Citations 12

Authors

Cesar Gomez Raposo

Alvaro Pinto Marin

Manuel Gonzalez Baron

Affiliations

Soon will be listed here.

Abstract

The hematopoietic growth factors (HGFs) are a family of glycoproteins which plays a major role in the proliferation, differentiation, and survival of primitive hematopoietic stem and progenitor cells, and in the functions of some mature cells. More than 20 different molecules of HGF have been identified. Among them, granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF) have been demostrated to be effective in reducing the incidence of febrile neutropenia when administered inmediately after chemotherapy and as supportive therapy in patients undergoing bone marrow transplantation. Chemotherapy used for treatment of cancer often causes neutropenia, which may be profound, requiring hospitalization, and leading to potentially fatal infection. The uses of the recombinant human hematopoietic colony-stimulating factors G-CSF and GM-CSF for treatment and prophylaxis of chemotherapy-induced febrile neutropenia will be reviewed here.

Citing Articles

[Effect of Intrauterine Perfusion of Granulocyte Colony-Stimulating Factor on Endometrium and Blood Flow Parameters in Patients With Thin Endometrium: A Prospective Controlled Clinical Trial].

Xu S, Ma Q, Zhang Y, An Y, He W, Ma Y Sichuan Da Xue Xue Bao Yi Xue Ban. 2024; 55(3):574-579.

PMID: 38948297 PMC: 11211764. DOI: 10.12182/20240560504.

Characterization of an Ex Vivo Equine Endometrial Tissue Culture Model Using Next-Generation RNA-Sequencing Technology.

Monteiro de Barros M, Davies-Morel M, Mur L, Creevey C, Alison R, Nash D Animals (Basel). 2021; 11(7).

PMID: 34359123 PMC: 8300099. DOI: 10.3390/ani11071995.

Long-term patient reported outcomes and hematologic toxicity among patients who received Granulocyte-Colony Stimulating Factors during chemotherapy for early breast cancer.

Lapidari P, Gbenou A, Havas J, Martin E, Pistilli B, Martin A Breast. 2021; 57:43-48.

PMID: 33711699 PMC: 7970125. DOI: 10.1016/j.breast.2021.02.014.

Comparison of biosimilar filgrastim with a reference product: pharmacokinetics, pharmacodynamics, and safety profiles in healthy volunteers.

Choi C, Yoo B, Kim C, Hong T, Jin B, Seo K Drug Des Devel Ther. 2018; 12:2381-2387.

PMID: 30122896 PMC: 6078186. DOI: 10.2147/DDDT.S158277.

Effectiveness of biosimilar filgrastim vs. original granulocyte colony-stimulating factors in febrile neutropenia prevention in breast cancer patients.

Puertolas I, Frutos Perez-Surio A, Alcacera M, Andres R, Salvador M Eur J Clin Pharmacol. 2017; 74(3):315-321.

PMID: 29152672 DOI: 10.1007/s00228-017-2365-5.

References

Lowenberg B, Suciu S, Archimbaud E, Ossenkoppele G, Verhoef G, Vellenga E . Use of recombinant GM-CSF during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia: final report of AML-11, a phase III randomized study of the Leukemia Cooperative Group of European.... Blood. 1997; 90(8):2952-61. View

Trillet-Lenoir V, Green J, Manegold C, von Pawel J, Gatzemeier U, Lebeau B . Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer. 1993; 29A(3):319-24. DOI: 10.1016/0959-8049(93)90376-q. View

Godwin J, Kopecky K, Head D, Willman C, Leith C, HYNES H . A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a Southwest oncology group study (9031). Blood. 1998; 91(10):3607-15. View

Hughes W, Armstrong D, Bodey G, Brown A, Edwards J, Feld R . 1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America. Clin Infect Dis. 1997; 25(3):551-73. DOI: 10.1086/513764. View

Freyer G, Ligneau B, Trillet-Lenoir V . Colony-stimulating factors in the prevention of solid tumors induced by chemotherapy in patients with febrile neutropenia. Int J Antimicrob Agents. 1998; 10(1):3-9. DOI: 10.1016/s0924-8579(98)00016-8. View

Birnbaum R, OMarcaigh A, Wardak Z, Zhang Y, Dranoff G, Jacks T . Nf1 and Gmcsf interact in myeloid leukemogenesis. Mol Cell. 2000; 5(1):189-95. DOI: 10.1016/s1097-2765(00)80415-3. View

Dombret H, Chastang C, Fenaux P, Reiffers J, Bordessoule D, Bouabdallah R . A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. AML Cooperative Study Group. N Engl J Med. 1995; 332(25):1678-83. DOI: 10.1056/NEJM199506223322504. View

Heil G, Hoelzer D, Sanz M, Lechner K, Liu Yin J, Papa G . A randomized, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia. The International Acute Myeloid Leukemia Study Group. Blood. 1998; 90(12):4710-8. View

Ravaud A, Chevreau C, Cany L, Houyau P, Dohollou N, Roche H . Granulocyte-macrophage colony-stimulating factor in patients with neutropenic fever is potent after low-risk but not after high-risk neutropenic chemotherapy regimens: results of a randomized phase III trial. J Clin Oncol. 1998; 16(9):2930-6. DOI: 10.1200/JCO.1998.16.9.2930. View

10.

Smith O, Reeves B, Kempski H, Evans J . Kostmann's disease, recombinant HuG-CSF, monosomy 7 and MDS/AML. Br J Haematol. 1995; 91(1):150-3. DOI: 10.1111/j.1365-2141.1995.tb05260.x. View

11.

Nichols C, Fox E, Roth B, Williams S, Loehrer P, Einhorn L . Incidence of neutropenic fever in patients treated with standard-dose combination chemotherapy for small-cell lung cancer and the cost impact of treatment with granulocyte colony-stimulating factor. J Clin Oncol. 1994; 12(6):1245-50. DOI: 10.1200/JCO.1994.12.6.1245. View

12.

Lyman G . Guidelines of the National Comprehensive Cancer Network on the use of myeloid growth factors with cancer chemotherapy: a review of the evidence. J Natl Compr Canc Netw. 2005; 3(4):557-71. DOI: 10.6004/jnccn.2005.0031. View

13.

Aviles A, Guzman R, Garcia E, Talavera A, Diaz-Maqueo J . Results of a randomized trial of granulocyte colony-stimulating factor in patients with infection and severe granulocytopenia. Anticancer Drugs. 1996; 7(4):392-7. DOI: 10.1097/00001813-199606000-00003. View

14.

Vellenga E, Uyl-de Groot C, de Wit R, Keizer H, Lowenberg B, Ten Haaft M . Randomized placebo-controlled trial of granulocyte-macrophage colony-stimulating factor in patients with chemotherapy-related febrile neutropenia. J Clin Oncol. 1996; 14(2):619-27. DOI: 10.1200/JCO.1996.14.2.619. View

15.

Johnson M, Grimwood R . Leukocyte colony-stimulating factors. A review of associated neutrophilic dermatoses and vasculitides. Arch Dermatol. 1994; 130(1):77-81. DOI: 10.1001/archderm.130.1.77. View

16.

Maher D, Lieschke G, Green M, Bishop J, Stuart-Harris R, Wolf M . Filgrastim in patients with chemotherapy-induced febrile neutropenia. A double-blind, placebo-controlled trial. Ann Intern Med. 1994; 121(7):492-501. DOI: 10.7326/0003-4819-121-7-199410010-00004. View

17.

Koyanagi Y, OBRIEN W, Zhao J, Golde D, Gasson J, Chen I . Cytokines alter production of HIV-1 from primary mononuclear phagocytes. Science. 1988; 241(4873):1673-5. DOI: 10.1126/science.241.4873.1673. View

18.

Riikonen P, Saarinen U, Makipernaa A, Hovi L, Komulainen A, Pihkala J . Recombinant human granulocyte-macrophage colony-stimulating factor in the treatment of febrile neutropenia: a double blind placebo-controlled study in children. Pediatr Infect Dis J. 1994; 13(3):197-202. DOI: 10.1097/00006454-199403000-00006. View

19.

Pettengell R, Gurney H, Radford J, Deakin D, James R, Wilkinson P . Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial. Blood. 1992; 80(6):1430-6. View

20.

Crawford J, Ozer H, Stoller R, Johnson D, Lyman G, Tabbara I . Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med. 1991; 325(3):164-70. DOI: 10.1056/NEJM199107183250305. View